Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report

References

• Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. doi:10.1038/s41571-022-00600-w
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249. doi:10.1146/annurev-pathol-042020-042741
   PubMed Web of Science ®Google Scholar
• Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. doi:10.1186/s12943-021-01489-2
   PubMed Web of Science ®Google Scholar
• Blank CU, Haining WN, Held W, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19(11):665–674. doi:10.1038/s41577-019-0221-9
   PubMed Web of Science ®Google Scholar
• Philip M, Fairchild L, Sun L, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545(7655):452–456. doi:10.1038/nature22367
   PubMed Web of Science ®Google Scholar
• Mitsuiki N, Schwab C, Grimbacher B. What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev. 2019;287(1):33–49. doi:10.1111/imr.12721
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi:10.1038/s41572-020-0160-6
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 2015;16(4):375–384. doi:10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25. doi:10.1016/j.ejca.2016.02.010
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22(16):4023–4029. doi:10.1158/1078-0432.CCR-15-2872
   PubMed Web of Science ®Google Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–361. doi:10.1007/s40257-017-0336-3
   PubMed Web of Science ®Google Scholar
• Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128. doi:10.1016/j.currproblcancer.2016.12.001
   PubMed Web of Science ®Google Scholar
• Wang WZ, Shulman A, Amann JM, Carbone DP, Tsichlis PN. Small cell lung cancer: subtypes and therapeutic implications. Semin Cancer Biol. 2022;86(Pt 2):543–554. doi:10.1016/j.semcancer.2022.04.001
   PubMedGoogle Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8. doi:10.1186/s40425-018-0316-z
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Shenoy N, Esplin B, Barbosa N, Wieland C, Thanarajasingam U, Markovic S. Pembrolizumab induced severe sclerodermoid reaction. Ann Oncol. 2017;28(2):432–433. doi:10.1093/annonc/mdw543
   PubMed Web of Science ®Google Scholar
• Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma induced by pembrolizumab: a case series. Mayo Clin Proc. 2017;92(7):1158–1163. doi:10.1016/j.mayocp.2017.03.016
   PubMed Web of Science ®Google Scholar
• Tjarks BJ, Kerkvliet AM, Jassim AD, Bleeker JS. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. J Cutan Pathol. 2018;45(8):615–618. doi:10.1111/cup.13273
   PubMed Web of Science ®Google Scholar
• Cho M, Nonomura Y, Kaku Y, et al. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma. J Dermatol. 2019;46(1):e43–e44. doi:10.1111/1346-8138.14492
   PubMed Web of Science ®Google Scholar
• Grant C, Chalasani V, Uchin JM, Dore A. Atezolizumab-induced scleroderma: a rare complication. BMJ Case Rep. 2021;14(11):e244968. doi:10.1136/bcr-2021-244968
   PubMedGoogle Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: clinical features and pathogenesis. J Am Acad Dermatol. 2022;87(5):937–954. doi:10.1016/j.jaad.2021.10.065
   PubMed Web of Science ®Google Scholar
• Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2(11):1507–1508. doi:10.1001/jamaoncol.2016.2238
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Internal Med. 2018;168(2):121–130. doi:10.7326/M17-2073
   PubMed Web of Science ®Google Scholar
• Pizuorno Machado A, Shatila M, Liu C, et al. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. J Cancer Res Clin Oncol. 2023;149(9):6341–6350. doi:10.1007/s00432-023-04582-9
   PubMed Web of Science ®Google Scholar
• Yamaguchi A, Saito Y, Okamoto K, et al. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis. Support Care Cancer. 2021;29(12):7747–7753. doi:10.1007/s00520-021-06359-7
   PubMed Web of Science ®Google Scholar
• Reid P, Cappelli LC. Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res. 2022;36(4):101805. doi:10.1016/j.berh.2022.101805
   Web of Science ®Google Scholar
• Terrier B, Humbert S, Preta LH, et al. Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmunity Rev. 2020;19(8):102596. doi:10.1016/j.autrev.2020.102596
   PubMed Web of Science ®Google Scholar
• Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71(3):468–475. doi:10.1002/art.40745
   PubMed Web of Science ®Google Scholar
• Macklin M, Yadav S, Jan R, Reid P. Checkpoint inhibitor-associated scleroderma and scleroderma mimics. Pharmaceuticals. 2023;16(2):1.
   Web of Science ®Google Scholar
• Mecoli CA, Casciola-Rosen L. An update on autoantibodies in scleroderma. Curr Opin Rheumatol. 2018;30(6):548–553. doi:10.1097/BOR.0000000000000550
   PubMed Web of Science ®Google Scholar
• Salazar GA, Assassi S, Wigley F, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheumatism. 2015;44(6):680–686. doi:10.1016/j.semarthrit.2014.11.006
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016
   PubMed Web of Science ®Google Scholar
• Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–1682. doi:10.1002/cncr.27969
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. doi:10.1016/j.ctrv.2016.02.001
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8
   PubMed Web of Science ®Google Scholar